. Author manuscript; available in PMC: 2022 Mar 1.

Published in final edited form as: Am J Reprod Immunol. 2020 Sep 21;85(3):e13343. doi: 10.1111/aji.13343

Table 3b.

CD14⁺HLA-DR^lo/- monocytic cells levels among serous ovarian cancer patients pre- and post-treatment, by disease stage.^‡

Median CD14⁺HLA-DR^lo/- monocytic cells % gated
Disease stage	Pre-treatment	Post-treatment	Median Decrease	P-value
Stage I/II (n=21)	4.93	3.57	1.18	0.19
Stage III/IV (n=49)	8.45	4.88	2.02	<0.0001

^‡

Among patients with available post-treatment CD14⁺HLA-DR^lo/- monocytic cells levels